Unfortunately, these drugs work on a specific cohort of tuberous sclerosis patients, harboring rare mutations in TSC1/TSC2, resulting in overactivating the PI3K-AKT–MTOR pathway (159, 282). This evidence concerns the gene MTOR and tuberous sclerosis.